Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04280289 · ClinicalTrials.gov registry record · Early Phase 1
CBD Cannabis Extract: Pharmacokinetic Studies
A Early Phase 1 study, sponsored by University of Mississippi, Oxford.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT04280289 is a Early Phase 1 study that has completed, run by University of Mississippi, Oxford. The registered enrollment target is 10 participants.
The verdict
NCT04280289, a Early Phase 1 study, has completed, sponsored by University of Mississippi, Oxford.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The initial goal is to ascertain the pharmacokinetic (PK) profile of CBD (cannabidiol) after a single dose of CBDE (cannabidiol extract), although the plan is to extend these studies to multiple dose administrations in the future, since it is likely that (cannabidiol) and/or its metabolites will show some accumulation. These studies will provide detailed information that will inform the continuation and expansion of CBDE in other research projects.
Interventions
- DRUG cannabidiol extract
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-02-01 |
| Est. Completion | 2021-12-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04280289
The ClinicalTrials.gov registry entry for NCT04280289 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Mississippi, Oxford, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which cannabidiol extract is the first listed.
NCT04280289 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04280289 about?
NCT04280289 is a clinical study titled "CBD Cannabis Extract: Pharmacokinetic Studies". The initial goal is to ascertain the pharmacokinetic (PK) profile of CBD (cannabidiol) after a single dose of CBDE (cannabidiol extract), although the plan is to extend these studies to multiple dose administrations in the future, since it is likely that (cannabidiol) and/or its metabolites will sho...
What is the current status of trial NCT04280289?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2021-02-01. Estimated completion is 2021-12-01.
What interventions are being tested in trial NCT04280289?
The interventions under investigation include: cannabidiol extract (DRUG).
Who is sponsoring clinical trial NCT04280289?
This trial is sponsored by University of Mississippi, Oxford, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.